Aptevo Therapeutics (APVO) Non-Current Deferred Tax Liability (2015 - 2016)
Aptevo Therapeutics (APVO) posted Non-Current Deferred Tax Liability of $15.8 million for Q2 2016, little changed sequentially from $15.8 million in Q1 2016.
Aptevo Therapeutics (APVO) Non-Current Deferred Tax Liability (2015 - 2016) Analysis & Trends
Aptevo Therapeutics has reported Non-Current Deferred Tax Liability for 2 years, with the latest figure at $15.8 million in Q2 2016.
- Quarterly Non-Current Deferred Tax Liability changed N/A year-over-year to $15.8 million in Q2 2016, while the trailing twelve-month figure through Jun 2016 was $15.8 million (changed N/A YoY) and the FY2015 annual result came in at $15.8 million, changed N/A from the prior year.
- Non-Current Deferred Tax Liability was little changed at $15.8 million in Q2 2016 per APVO's latest filing, from $15.8 million in the prior quarter.
- Over five years, Non-Current Deferred Tax Liability peaked at $15.8 million in Q4 2015 and troughed at $15.8 million in Q4 2015.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - |
| 10 | Aptevo Therapeutics | 3.18 Mn | -6.61 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2016 | 15.82 Mn |
| Jun 30, 2016 | 15.82 Mn |
| Mar 31, 2016 | 15.82 Mn |
| Mar 31, 2016 | 15.82 Mn |
| Dec 31, 2015 | 15.82 Mn |
| Dec 31, 2015 | 15.82 Mn |